Therapeutic drug monitoring, pharmacokinetics (half-life, elimination rate, AUC), dose individualization, and steady-state kinetics.
Adjusts a standard adult dose by the patient's BSA relative to 1.73 m2.
Dose-to-AUC and AUC-to-dose conversions for linear pharmacokinetics: AUC = Dose / Clearance, and Dose = AUC × Clearance. Converts between a dose (mg) and the corresponding exposure (AUC, mg·h/L) given drug clearance (L/h).
Dosing-weight conversions: ideal body weight (Devine), adjusted body weight (IBW + 0.4 × (actual − IBW)), recommended dosing weight (actual weight if ≤ IBW, else adjusted), and lean body weight (Janmahasatian 2005). Used to select the appropriate weight for weight-based drug dosing (e.g. aminoglycosides, chemotherapy).
Drug half-life from two concentrations in the elimination phase: Ke = ln(C1/C2)/(t2−t1), then t½ = 0.693/Ke. Both levels must be drawn after distribution is complete.
Elimination rate constant (Ke) from a single TDM concentration using a one-compartment IV-bolus model: C(t) = (Dose/Vd) × e^(−Ke×t), so Ke = ln((Dose/Vd)/C) / t. Requires dose, volume of distribution, the measured concentration, and time since the dose. Approximate — prefer the two-level method when available.
Elimination rate constant (Ke) from two therapeutic drug monitoring concentrations in the elimination phase: Ke = ln(C1/C2) / (t2 − t1). Also reports half-life (0.693/Ke). Both levels must be drawn after distribution is complete.
Non-compartmental pharmacokinetic analysis from a concentration-time profile: AUC (linear trapezoidal with extrapolated tail), elimination rate constant Ke (log-linear regression on terminal points), half-life, clearance (Dose/AUC), and volume of distribution (CL/Ke). Enter times with concentrations; the last 3 points define the terminal phase by default.
Selects the nearest practical dose and dosing interval: given a calculated dose and the available tablet/capsule strengths, returns the closest available strength (and its percent deviation); given a calculated interval in hours, snaps to the nearest standard interval (q4h, q6h, q8h, q12h, q24h, q48h, q72h). A prescribing practicality aid — confirm the rounded regimen is therapeutically appropriate.
One-compartment pharmacokinetic dose individualization for intermittent IV dosing at steady state. Predict mode: Cmax_ss and Cmin_ss from dose, Vd, Ke, and interval (IV bolus or infusion). Dose-for-target mode: solves the dose needed to achieve a target trough (bolus). Standard steady-state equations.
Two-compartment pharmacokinetic steady-state prediction for intermittent IV bolus dosing, using macro-constants (C(t) = A×e^(−αt) + B×e^(−βt) per dose). Superposition gives Cmax_ss = A/(1−e^(−ατ)) + B/(1−e^(−βτ)) and Cmin_ss with each term decayed over the interval. A, B from a fitted bolus profile; α > β.
Steady-state kinetics: accumulation ratio R = 1/(1 − e^(−Ke×τ)), fraction of steady state after n doses = 1 − e^(−n×Ke×τ), and time to reach a target fraction of steady state in half-lives (n½ = −ln(1−f)/ln 2). Enter Ke or half-life plus the dosing interval.
Convert between glucocorticoid equivalents.
AUC-guided vancomycin dosing check via the two-concentration method: elimination rate constant Ke from two timed levels, clearance from Ke × Vd (0.7 L/kg), then AUC24 = total daily dose / clearance. Target AUC24 400-600 mg·h/L (AUC/MIC 400-600) per the 2020 vancomycin guidelines.
Computes the vancomycin AUC24/MIC ratio from a known 24-hour area under the curve and pathogen MIC. Target 400-600 for serious MRSA infections per the 2020 vancomycin consensus guideline.
Clinical Decision Support (CDS) Notice & Legal Disclaimer
All calculations and clinical scoring tools in this directory are intended strictly for educational and decision-support use by licensed medical practitioners. They do not constitute autonomous medical advice or direct treatment orders. See the full DexaMed Medical Disclaimer.